Cardiac Drugs 1 Flashcards
Procainamide HCl (Pronestyl) Class
Antidysrhythmic
Procainamide HCl (Pronestyl) mechanism of action
Suppresses phase 4 depolarization in normal ventricular muscle and purkinje fibers, reducing ectopic pacemaker’s automaticity; suppresses intraventricular conduction.
Procainamide HCl (Pronestyl) Iindications
Stable monomorphic VT with normal QT interval, reentry SVT uncontrolled by vagel maneuvers and adenosine, stable wide-complex tachycardia of unknown origin, AF with rapid ventricular rate in patients with Wolff parkinson white syndrome.
Procainamide HCl (Pronestyl) contraindications
Torsades de pointes, second and third degree heart AV block(without functioning artificial pacemaker), preexisting QT prolongation, digitalis toxicity, tricyclic antidepressant overdose.
Procainamide HCl (Pronestyl) adverse reactions/side effects
Confusion, seizures, hypotension, bradycardia, reflex tachycardia, centricular dysrhythmias, AV blocks, asystole, widening of PR, QRS, and QT intervals, nausea, vomiting
Procainamide HCl (Pronestyl) drug interactions
increases plasma levels of amiodarone and quinidine
Procainamide HCl (Pronestyl) dosage and administration adult (recurrent VF/pulseless VT)
20mg/min slow IV infusion until the dysrythmia is suppressed, hypotension, QRS widens by greater than 50% of its pretreatment width,
If urgent up to 50 mg/min
max of 17mg/kg
Procainamide HCl (Pronestyl) adult maintenence dose
1 to 4 mg/min in saline or d5w
Procainamide HCl (Pronestyl) duration of action
onset: 10 to 30 minutes,
peak: variable
Duration: 3 to 6 hours
Procainamide HCl (Pronestyl) pregnancy safety category
Category C
Procainamide HCl (Pronestyl) pediatric dosage and administration
loading dose of 15 mg/kg IV/IO over 30 to 60 mins.
Procainamide HCl (Pronestyl) special considerations
Potent vasodialation and negative inotropic effects. Hypotension may occur with rapid infusion. administer cautiously to patients with cardiac, hepatic, or renal insufficiency. asthma or digitalis induced dysrythmias.
Adenosine(Adenocard) class
Antidysrhythmic
Adenosine(Adenocard) mechanism of action
Slows conduction through the AV node, can interrupt reentrant AV nodal pathways.
Adenosine(Adenocard) indications
Conversion of narrow complex regular tachycardia to sinus rhythm. May conver reentry SVT due to wolf parkinson white syndrome. Can be used diagnostically for stable, regular, monomorphic wide complex tachycardia. Adenosine may treat the VT or it may help diagnose the underlying rhythm.
Adenosine(Adenocard) contraindications
hypersensitivity, second or third degree av block, sick sinus syndrome, other sinus node disease unless a funcioning artificial pacemaker is present; bronchoconstrictive or bronchospastic lung disease(COPD, Asthma), poison or drug induced tachycardia.
Adenosine(Adenocard) adverse reactions/side effects
Generally short duration and mild; headache, dizziness, dyspnea, bronchospasm, dysrhythmias, palpitations, hypotension, chest pain, facial flushing, cardiac arrest, nausea, metallic taste, pain in the head or neck, paresthesia, diaphoresis.
Adenosine(Adenocard) drug interactions
methylxanthines antagonize the effects of adenosine. Dipyridamole potentiates the effect of adenosine, carbamazepine(Tegretol) may potentiate the AV node blocking effect of adenosine.
Adenosine(Adenocard) adult dosage and administration
6 mg rapid IV bolus over 1-3 seconds, followed by a 20 mL saline flush and elevate the extremity. If no response after 1-2 minutes administer second dose of 12mg.
Adenosine(Adenocard) pediatric dosage and administration
initial dose of 0.1 mg/kg rapid IV/IO push, second dose 0.2mg/kg rapid IV/IO push. maximum second dose of 12mg
Adenosine(Adenocard) duration of action
onset: seconds
peak effect: seconds
duration: 12 seconds
Adenosine(Adenocard) pregancy safety category
C
Adenosine(Adenocard) special considerations
Not effective in converting AF or atrial flutter or VT. Short half life limits advers effects in most patients. brief period of most any dysrhythmia, including asystole may occur during pharmacological conversion. Reduce the dose by one half in patients on dipyridamole(Persantine), carbamazepine(Tegretol), those with transplanted hearts, or given via a central IV line
Amiodorone(Cardarone, Pacerone) class
Antidysrhythmic
Amiodorone(Cardarone, Pacerone) mechanism of action
Blocks sodium, potassium, and calcium channels; prolongs the action potential and repolarization; decreases AV conduction and sinoatrial(SA) node function.
Amiodorone(Cardarone, Pacerone) indications
Stable, regular narrow complex tachycardia if the rhythm persists despite vagal maneuvers or adenosine or the tachycardia is recurrent; to control the ventricular rate in stable, irregular narrow complex tachycardia(AF); to control the ventricular rate in preexcited atrial dysrhythmias with conduction over and accessory pathway; stable monomorphic VT; polymorphic VT with a normal QT interval; cardiac arrest resulting from VF or pulseless VT after CPR, defibrillation, and a vasopressor.
Amiodorone(Cardarone, Pacerone) contraindications
hypersensitivity, cardiogenic shock, second or third degree AV block or sick sinus syndrome or other sinus node disease unless a funtioning artificial pacemaker is present
Amiodorone(Cardarone, Pacerone) adverse reactions/side effects
Dizziness, fatigue, malaise, tremor, ataxia, lack of coordination, ARDS, pulmonary edema, cough, progressive dyspnea, heart failure, bradycardia, hypotension, worsening of dysrhythmias, prolonged QT interval, nausea, vomiting, burning at IV site, stevens johnson syndrome.
Amiodorone(Cardarone, Pacerone) drug interactions
Use with digoxin may cause digitalis toxicity. Beta blockers and calcium channel blockers may potentiate bradycardia, sinus arrest, and AV blocks.
Amiodorone(Cardarone, Pacerone) adult dosage and administration for VF/pulseless VT
300 mg IV/IO push. initial dose can be followed once in 3 to 5 mins at 150 mg IV/IO push.
Amiodorone(Cardarone, Pacerone) adult dosage for other indications(not VF/pulselessVT)
Loading dose of 150 mg IV/IO over 10 minutes; may repeat every 10 minutes if needed.
Amiodorone(Cardarone, Pacerone) adult maintenance dosage
after conversion, follow with a 1mg/min infusion for 6 hours and then .5 mg/min maintenence infusion over 18 hours. maximum cumulative dosage of 2.2 IV/IO per 24 hours.
Amiodorone(Cardarone, Pacerone) pediatric dosage refractory VF/pulseless VT
5mg/kg IV/IO bolus. Can repeat the 5mg/kg IV/IO bolus up to a total dose of 15 mg/kg per 24 hours(2.2 g in adolescents) maximum single dose 300mg
Amiodorone(Cardarone, Pacerone) pediatric dosage for perfusing ventricular or atrial dysrhythmias
Loading dose 5mg/kg IV/IO over 20 to 60 mins(maximum single dose of 300mg) can repeat to a maximum dose of 15 mg/kg per day(2.2g in adolescents.)
Amiodorone(Cardarone, Pacerone) duration of action
onset: 2 hours
peak effect: 3 to 7 hours
duration: unknown
Amiodorone(Cardarone, Pacerone) pregancy safety category
D; drug may cause fetal harm. fetal risk and maternal benefit should be considered in the mergency setting. Lactating women should not breastfeed following use.
Amiodorone(Cardarone, Pacerone) special considerations
may worsen or precipitate new dysrhythmias. Monitor the patient for hypotension and increasing PR and QT intervals. Dosage may change in accordance with the most current ILCOR recommendations.
Atropine Sulfate class
anticholinergic agent
Atropine Sulfate mechanism of action
inhibits the action of acetylcholine at postganglionic parasympathetic neuroeffector sites. increases heart rate in symptomatic bradydysrhythmias
Atropine Sulfate indications
hemodynamically unstable bradycardia, organophosphate poisoning, nerve agent exposure, RSI in pediatrics, beta-blocker or calcium channel blocker overdose.
Atropine Sulfate contraindications
Tachycardia, hypersensitivity, unstable cardiovascular status in acute hemorrhage with miocardial ishemia, narrow angle glaucoma, hypothermic bradycardia.
Atropine Sulfate adverse reactions/side effects
drowsiness, confusion, headache, tachycardia, palpitations, dysrhythmias, nausea, vomiting, pupil dilation, dry mouth/nose/skin, blurred vision, urinary retention, constipation, flushed, hot, dry skin; paradoxical bradycardia when pushed too slowly or when given at low doses.
Atropine Sulfate drug interactions
Potential adverse effects when administered with digitalis, cholinergics, physostigmine. Effects enhanced by antihistamines, procainamide, quinidine, antipsychotics, benzodiazepines, and antidepressants.
Atropine Sulfate adult dose for unstable bradycardia
0.5 mg IV/IO infussion every 3 to 5 mins as needed; maximum total dose of 3mg total. Use shorter dosage intervals and higher doses in severe clinical conditions.
Atropine Sulfate adult dosage for organophosphate poisoning
extremely large doses(2 to 4mg) may be needed.
Atropine Sulfate pediatric unstable bradycardia dosage
0.02mg/kg IV/IO(minimum dosage: 0.01) may repeat once. maximum single dose child: 0.5mg, adolescent:1mg: Maximum total dose child:1mg, adolescent: 3mg.
Atropine Sulfate pregnancy class
C
Atropine Sulfate special considerations
Moderate doses may cause pupillary dilation. Paradoxical bradycardia can occur with doses lower than 0.1 mg. May be ineffective in patients who have had a heart transplant or in infranodal AV blocks.